232 related articles for article (PubMed ID: 35990518)
21. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
22. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
23. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
24. Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells.
Willier S; Raedler J; Blaeschke F; Stenger D; Pazos Escudero M; Jurgeleit F; Grünewald TGP; Binder V; Schmid I; Albert MH; Wolf A; Feuchtinger T
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938628
[TBL] [Abstract][Full Text] [Related]
25. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Tong C; Zhang Y; Liu Y; Ji X; Zhang W; Guo Y; Han X; Ti D; Dai H; Wang C; Yang Q; Liu W; Wang Y; Wu Z; Han W
Blood; 2020 Oct; 136(14):1632-1644. PubMed ID: 32556247
[TBL] [Abstract][Full Text] [Related]
26. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Ahmed N; Kumar A; Kharfan-Dabaja MA; DeFilipp Z; Herrera A; Hashmi S; Dholaria B; Perales MA; Carpenter PA; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):523-529. PubMed ID: 35671986
[TBL] [Abstract][Full Text] [Related]
27. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
29. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
[TBL] [Abstract][Full Text] [Related]
30. How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
de Ramon Ortiz C; Wang S; Stathis A; Bertoni F; Zenz T; Novak U; Simonetta F
Hematol Oncol; 2024 Jan; 42(1):e3237. PubMed ID: 37937474
[TBL] [Abstract][Full Text] [Related]
31. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.
Xu H; Li N; Wang G; Cao Y
Front Immunol; 2023; 14():1110028. PubMed ID: 37051246
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
33. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
34. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
Schneider D; Xiong Y; Wu D; Hu P; Alabanza L; Steimle B; Mahmud H; Anthony-Gonda K; Krueger W; Zhu Z; Dimitrov DS; Orentas RJ; Dropulić B
Sci Transl Med; 2021 Mar; 13(586):. PubMed ID: 33762438
[TBL] [Abstract][Full Text] [Related]
35. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
36. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
38. Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B; Ramírez-Fernández Á; Bueno C; Argemí-Muntadas L; Fuentes P; Aguilar-Sopeña Ó; Gutierrez-Agüera F; Zanetti SR; Tapia-Galisteo A; Díez-Alonso L; Segura-Tudela A; Castellà M; Marzal B; Betriu S; Harwood SL; Compte M; Lykkemark S; Erce-Llamazares A; Rubio-Pérez L; Jiménez-Reinoso A; Domínguez-Alonso C; Neves M; Morales P; Paz-Artal E; Guedan S; Sanz L; Toribio ML; Roda-Navarro P; Juan M; Menéndez P; Álvarez-Vallina L
Cancer Immunol Res; 2022 Apr; 10(4):498-511. PubMed ID: 35362043
[TBL] [Abstract][Full Text] [Related]
39. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Ruella M; Barrett DM; Kenderian SS; Shestova O; Hofmann TJ; Perazzelli J; Klichinsky M; Aikawa V; Nazimuddin F; Kozlowski M; Scholler J; Lacey SF; Melenhorst JJ; Morrissette JJ; Christian DA; Hunter CA; Kalos M; Porter DL; June CH; Grupp SA; Gill S
J Clin Invest; 2016 Oct; 126(10):3814-3826. PubMed ID: 27571406
[TBL] [Abstract][Full Text] [Related]
40. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
Bouziana S; Bouzianas D
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]